AZD8630/AMG 104, an inhaled Anti-TSLP antibody fragment, for moderate-to-severe asthma: a phase 1 randomized controlled trial

AZD8630/AMG 104, an inhaled Anti-TSLP antibody fragment, for moderate-to-severe asthma: a phase 1 randomized controlled trial | ReachRx